History of Avanir
Founded with focus
Avanir started out as Lidak Pharmaceuticals (Lidak) in 1988, developing research-based treatments to meet patients’ needs.
Avanir changed its name from Lidak Pharmaceuticals to Avanir Pharmaceuticals.
CNS at the Forefront
Avanir obtained NDA approval for its first pharmaceuticals products, Abreva®, an over-the-counter cold sore treatment.
In October, we received an FDA approval for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) with a 20/10 mg dose strength.
NUEDEXTA® is launched in the United States
Avanir entered into a license agreement with Concert Pharmaceuticals, Inc. to develop and commercializedeuterium-modified dextromethorphan for disorders of the central nervous system.
Entered into Agreement with OptiNose®
On July 2, Avanir announced a development and commercialization agreement with OptiNose® AS for a newinvestigational product for the acute treatment of migraine.
In 2015, Avanir became a subsidiary of Otsuka America, Inc., a holding company owned by Otsuka Pharmaceutical Co., Ltd. This move provided the support of a leading global pharmaceutical company while allowing our business to remain nimble and flexible.
ONZETRA® Xsail® approved
(sumatriptan nasal powder) 11 mg per nosepiece
Avanir received FDA approval of ONZETRA® Xsail® in January and launched it in the United States market in May.
Copyright: AVANIR, NUEDEXTA, ONZETRA XSAIL and Avanir logos are trademarks or registered trademarks of Avanir Pharmaceuticals, Inc. in the United States or other countries. All other marks, logos and trade names are the trademarks of their respective owners and appear by permission of those owners. You may not reproduce, download or otherwise use any such trademarks, service marks, logos or trade names without the prior written consent of Avanir Pharmaceuticals, Inc. or the appropriate owner thereof. The use of names, trademarks, and logos not owned by Avanir Pharmaceuticals, Inc. does not imply endorsement of products and services associated therewith.